Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 19, 2026
Arm Holdings (ARM) Stock Plunges -39% Over 30 Days: Valuation Concerns and Sector Pressures at Play

Arm Holdings (ARM) Stock Plunges -39% Over 30 Days: Valuation Concerns and Sector Pressures at Play

Key Takeaways

  • Arm Holdings shares dropped approximately 39% over the last 30 days, sliding from around $439 on June 18 to $267 on July 17, as a convergence of analyst downgrades, valuation concerns, and AI-sector rotation triggered sharp selling pressure.
  • Over the broader quarter, the stock remains up roughly 60% despite the recent pullback, reflecting the powerful rally that preceded the June peak above $452 before the selloff began.
  • HSBC's downgrade from Buy to Hold on July 15, paired with New Street Research cutting its rating to Neutral in late June, amplified concerns that ARM's valuation had outpaced near-term fundamentals.
  • TSMC's limited 3-nanometer foundry capacity emerged as a critical bottleneck, constraining how quickly Arm can convert booming AI chip demand into royalty revenue growth.
  • Macroeconomic headwinds—including hotter-than-expected June CPI data and rising odds of additional Federal Reserve rate hikes—disproportionately punished richly valued chip stocks like ARM.
  • Arm reports fiscal first-quarter earnings on July 29, with consensus estimates at $0.36 EPS on $1.27 billion in revenue, making the upcoming report a pivotal catalyst for near-term sentiment.

Arm Holdings (ARM) Company Overview and Market Position

Arm Holdings plc designs and licenses central processing unit (CPU) intellectual property, graphics processing unit IP, system IP, and compute subsystems used by virtually every major semiconductor company worldwide. Its energy-efficient architecture dominates the smartphone and embedded-device markets and is rapidly expanding into data center servers, automotive electronics, and artificial intelligence infrastructure. Unlike traditional chipmakers, Arm operates a capital-light licensing and royalty model: it earns upfront license fees when partners adopt its designs and recurring royalty payments when those chips ship in volume. This model has made Arm's architecture the foundation for chips from AAPL, NVDA, AMZN, GOOGL, and QCOM, among hundreds of others, and placed the company at the center of the AI computing buildout. I also checked comparable names in the sector using Tickeron’s AI Screener to see how ARM stacks up on valuation metrics.

Arm Holdings (ARM) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 days, Arm Holdings shares have fallen approximately 39%, declining from a closing price of $439.46 on June 18 to $267.19 on July 17. The selloff was not linear: the stock dropped roughly 7% in a single session on June 23 after New Street Research downgraded the name, then experienced another sharp leg lower on July 14–15 following HSBC's downgrade and broader chip-sector weakness. Momentum indicators turned firmly defensive, with the stock slipping well below its 20-day simple moving average of approximately $356 and its Relative Strength Index falling to near-neutral territory around 47. One thing that stands out here is how quickly sentiment shifted after the June peak.

Looking at the broader quarter, the picture is more nuanced. From mid-April levels around $167, ARM surged more than 170% to its all-time peak of $452.70 on June 18 before the current drawdown erased much of those gains. The quarterly net gain of roughly 60% underscores that the 30-day decline represents a sharp retracement within a longer-term uptrend, driven by a powerful AI-fueled rally that began accelerating in late April and early May. The stock remains well above its 200-day moving average of approximately $181, signaling that the longer-term structural uptrend is intact despite the severe short-term correction. From what I see, the longer-term uptrend still holds despite the volatility.

What Drove ARM Stock Price in the Last 30 Days

The 39% decline over the last 30 days was driven by multiple reinforcing catalysts rather than a single event. The most prominent trigger was HSBC's July 15 downgrade from Buy to Hold: the bank raised its price target to $315 but argued that ARM's AI-driven rally had already priced in much of its long-term growth story, with the stock trading at roughly 139 times fiscal 2027 earnings. Weeks earlier, New Street Research cut its rating to Neutral, citing similar overvaluation concerns after the stock's parabolic rise.

Compounding the analyst caution was a structural reality investors could no longer ignore: TSMC's limited 3-nanometer foundry capacity. ARM's management acknowledged that AGI CPU demand—which management pegged above $20 billion—currently faces only about $1 billion in available manufacturing capacity, creating a near-term ceiling on how quickly licensing momentum translates into royalty income.

Macroeconomic forces added further pressure. The June Consumer Price Index reading of 4.2% year-over-year—the hottest in three years—reignited fears of additional Federal Reserve rate hikes, and Bank of America subsequently forecast three more 25-basis-point increases in 2026. Because ARM trades at an extreme valuation premium built on future earnings, it is unusually sensitive to rising rates, which discount the present value of distant profits more aggressively than they do for mature cyclicals. Institutional money flow data confirmed that large buyers began retreating in mid-June, with Chaikin Money Flow collapsing from 0.37 to near zero, while put-call ratios flipped bearish. Profit-taking after a year-to-date surge exceeding 170% added further selling pressure, and insider stock sales contributed to the negative sentiment backdrop.

What Drove ARM Stock Performance Over the Last Quarter

ARM's quarterly performance tells a story of two extremes. The period from mid-April through mid-June delivered one of the most remarkable rallies in the semiconductor sector, fueled by blockbuster fiscal 2026 results that included $1.49 billion in Q4 revenue and surging licensing demand. The company's "Arm Everywhere" event in March continued to resonate, as investors embraced the narrative that ARM architecture would become the default CPU foundation for AI data centers. Major hyperscalers—including META, GOOGL, and MSFT—were reported to be building ARM-based custom silicon, while Wall Street analysts including TD Cowen (target $475), UBS ($470), and Mizuho ($500) set ambitious price targets tied to the long-term AI CPU opportunity. ARM's licensing model and the royalty uplift from its higher-value Armv9 architecture provided additional fundamental support. However, the same quarter ended with a harsh reassessment as valuation gravity, capacity constraints, and macro anxiety triggered the sharp correction that now defines the stock's near-term trajectory.

Exploring Data-Driven Approaches in Volatile Markets

In volatile market environments like the one currently affecting semiconductor and AI stocks, I often look to systematic strategies for disciplined entry and exit signals. Tickeron's Trending AI Robots page curates a focused selection of top-performing AI-powered trading bots drawn from a universe of hundreds of bots trading thousands of tickers across equities, ETFs, and forex. Only bots demonstrating strong recent performance and statistical relevance appear in this section, giving traders a streamlined view of strategies that have adapted successfully to prevailing market conditions. The bots vary widely in approach—some specialize in short-term momentum, others in swing trading or mean-reversion—and each displays transparent performance metrics including win rates, trade frequency, and drawdown statistics. For investors navigating the sharp reversals in names like ARM, exploring data-driven bot strategies can provide an additional analytical lens. I’m watching this closely as a way to complement fundamental analysis.

ARM Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst for ARM is its fiscal Q1 2026 earnings report scheduled for July 29, where analysts expect $0.36 in earnings per share on $1.27 billion in revenue. Investors will scrutinize royalty revenue guidance, which serves as the most direct indicator of whether TSMC's capacity constraints are easing enough to allow customer shipments—and thus Arm's royalty income—to accelerate. Any update on AGI CPU order conversion, licensing pipeline visibility, and progress in data center design wins with major hyperscalers will be critical. Beyond earnings, the trajectory of Federal Reserve policy remains a key risk: further hawkish signals would likely weigh disproportionately on ARM's premium valuation. On the competitive front, the Qualcomm-Nuvia trial expected in Q4 2026 and the ongoing evolution of open-source RISC-V architecture represent potential long-term risks to ARM's IP moat. For bullish investors, signs that TSMC is accelerating 3-nanometer capacity expansion in the second half of 2027 would directly address the bottleneck that HSBC and other analysts identified as the primary constraint on near-term growth. I also reviewed recent pattern activity with Tickeron’s AI Real Time Patterns to stay on top of any emerging signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARM

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ARM's Indicator enters downward trend

The Aroon Indicator for ARM entered a downward trend on August 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 87 similar instances where the Aroon Indicator formed such a pattern. In of the 87 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

ARM moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARM crossed bearishly below the 50-day moving average on July 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARM's RSI Indicator exited the oversold zone, of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on ARM as a result. In of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARM just turned positive on August 04, 2026. Looking at past instances where ARM's MACD turned positive, the stock continued to rise in of 25 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARM advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (35.461) is normal, around the industry mean (16.094). P/E Ratio (292.531) is within average values for comparable stocks, (162.735). Projected Growth (PEG Ratio) (2.354) is also within normal values, averaging (1.904). ARM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (59.524) is also within normal values, averaging (47.773).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), Analog Devices (NASDAQ:ADI), QUALCOMM (NASDAQ:QCOM).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 187.57B. The market cap for tickers in the group ranges from 13.43K to 5.31T. NVDA holds the highest valuation in this group at 5.31T. The lowest valued company is CYBL at 13.43K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 11%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 48%. SITM experienced the highest price growth at 30%, while ON experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 48
SMR Rating: 75
Profit Risk Rating: 73
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
ARM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry Semiconductors

Profile
Details
Industry
N/A
Address
110 Fulbourn Road
Phone
+44 1223400400
Employees
8330
Web
https://www.arm.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.